Photodynamic therapy with Pd-Bacteriopheophorbide (TOOKAD): Successful in vivo treatment of human prostatic small cell carcinoma xenografts

International Journal of Cancer

Volumn 104, Issue 6, 2003, Pages 782-789

  Koudinova, Natalia V ^a   Pinthus, Jehonathan H ^a,b   Brandis, Alexander ^a   Brenner, Ori ^a   Bendel, Peter ^a   Ramon, Jacob ^b   Eshhar, Zelig ^a   Scherz, Avigdor ^a   Salomon, Yoram ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

Bone metastasis; Palladium Bacteriopheophorbide; Photodynamic therapy; Small cells carcinoma of prostate; Xenograft

Indexed keywords

BACTERIOCHLOROPHYLL; CHROMOGRANIN A; PALLADIUM; PALLADIUM BACTERIOPHEOPHORBIDE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BONE METASTASIS; CONTROLLED STUDY; DIODE LASER; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; PHOTODYNAMIC THERAPY; PHOTOSENSITIZATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; SMALL CELL CARCINOMA; TREATMENT OUTCOME; TUMOR BLOOD FLOW; XENOGRAFT;

ANIMALS; BACTERIOCHLOROPHYLLS; BONE DISEASES; CARCINOMA, SMALL CELL; CHROMOGRANIN A; CHROMOGRANINS; HUMANS; IMMUNOENZYME TECHNIQUES; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, NUDE; MODELS, ANIMAL; NEOPLASM TRANSPLANTATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PROSTATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME; TUMOR CELLS, CULTURED;

EID: 0344838384     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11002     Document Type: Article

References (55)

1. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol 1992;55:145-57.
2. Kato H, Patrice T, Wilson B. Photodynamic therapy. In: Johnson S, Johnson FN, eds. Review of Contemporary Pharmacotherapy. London: Marius Press, 1999. 1-78.
3. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q. Photodynamic therapy. J Natl Cancer Inst 1998;90:889-905.
4. Macdonald IJ, Dougherty TJ. Basic principles of photodynamic therapy. J Porphyrins Phthalocyanines 2001;5:105-29.
5. Peng Q, Soler AM, Warloe T, Nesland JM, Giercksky K. Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate. J Photochem Photobiol B 2001;62:140-5.
6. Kubler AC, Haase T, Staff C, Kahle B, Rheinwald M, Muhling J. Photodynamic therapy of primary nonmelanomatous skin tumours of the head and neck. Lasers Surg Med 1999;25:60-8.
7. Maier A, Tomaselli F, Matzi V, Rehak P, Pinter H, Smolle-Juttner FM. Photosensitization with hematoporphyrin derivative compared to 5-aminolaevulinic acid for photodynamic therapy of esophageal carcinoma. Ann Thorac Surg 2001;72:1136-40.
8. Ost D. Photodynamic therapy in lung cancer. Oncology (Huntington) 2000;14:379-86, 91; discussion 91-2, 95.
9. Moghissi K, Dixon K, Stringer M, Freeman T, Thorpe A, Brown S. The place of bronchoscopic photodynamic therapy in advanced unresectable lung cancer: experience of 100 cases. Eur J Cardiothorac Surg 1999;15:1-6.
10. D'Hallewin MA, Baert L. Long-term results of whole bladder wall photodynamic therapy for carcinoma in situ of the bladder. Urology 1995;45:763-7.
11. Zupko I, Kamuhabwa AR, D'Hallewin MA, Baert L, De Witte PA. In vivo photodynamic activity of hypericin in transitional cell carcinoma bladder tumors. Int J Oncol 2001;18:1099-105.
12. Nseyo UO. Photodynamic therapy in the management of bladder cancer. J Clin Laser Med Surg 1996;14:271-80.
13. Nseyo UO, DeHaven J, Dougherty TJ, Potter WR, Merrill DL, Lundahl SL, Lamm DL. Photodynamic therapy (PDT) in the treatment of patients with resistant superficial bladder cancer: a long-term experience. J Clin Laser Med Surg 1998;16:61-8.
14. Pantelides ML, Whitehurst C, Moore JV, King TA, Blacklock NJ. Photodynamic therapy for localised prostatic cancer: light penetration in the human prostate gland. J Urol 1990;143:398-401.
15. Whitehurst C, Pantelides ML, Moore JV, Blacklock NJ. Optimization of multifiber light delivery for the photodynamic therapy of localized prostate cancer. Photochem Photobiol 1993;58:589-93.
16. Whitehurst C, Pantelides ML, Moore JV, Brooman PJ, Blacklock NJ. In vivo laser light distribution in human prostatic carcinoma. J Urol 1994;151:1411-5.
17. Lee LK, Whitehurst C, Pantelides ML, Moore JV. In situ comparison of 665 nm and 633 nm wavelength light penetration in the human prostate gland. Photochem Photobiol 1995;62:882-6.
18. Chen Q, Hetzel F. Laser dosimetry studies in the prostate. J Clin Laser Med Surg 1998;16:9-12.
19. Arnfield MR, Chapman JD, Tulip J, Fenning MC, McPhee MS. Optical properties of experimental prostate tumors in vivo. Photochem Photobiol 1993;57:306-11.
20. Chang SC, Buonaccorsi GA, MacRobert AJ, Bown SG. Interstitial photodynamic therapy in the canine prostate with disulfonated aluminum phthalocyanine and 5-aminolevulinic acid-induced protoporphyrin IX. Prostate 1997;32:89-98.
21. Momma T, Hamblin MR, Wu HC, Hasan T. Photodynamic therapy of orthotopic prostate cancer with benzoporphyrin derivative: local control and distant metastasis. Cancer Res 1998;58:5425-31.
22. Moore RB, Chapman JD, Mercer JR, Mannan RH, Wiebe LI, Mc-Ewan AJ, McPhee MS. Measurement of PDT-induced hypoxia in Dunning prostate tumors by iodine-123-iodoazomycin arabinoside. J Nucl Med 1993;34:405-11.
23. Chen Q, Huang Z, Luck D, Beckers J, Brun PH, Wilson BS, Scherz A, Salomon Y, Hetzel FW. Preclinical studies in normal canine prostate of a novel Palladium-Bacteriopheophorbide (WST09) photosensitizer for photodynamic therapy of prostate cancer. Photochem Photobiol 2002;76:438-45.
24. Windahl T, Andersson SO, Lofgren L. Photodynamic therapy of localised prostatic cancer. Lancet 1990;336:1139.
25. Kessel D, Dougherty T. Agents used in photodynamic therapy. In: Johnson S, Johnson FN, eds. Review of Contemporary Pharmacotherapy. London: Marius Press, 1999. 19-24.
26. Scherz A, Feodor L, Salomon Y. Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmacological compositions comprising them. Patent Application No. 5,650,292. USA, 1997.
27. Scherz A, Fiedor L, Salomon Y. Chlorophyll and bacteriochlorophyll derivatives, their preparation and pharmaceutical compositions comprising them. II. Patent Application No. 5,726,169. USA, 1998.
28. Scherz A, Salomon Y, Scheer H, Brandis A. Palladium-substituted bacteriochlorophyll derivatives and use thereof. International PCT Patent Application No. PCT/IL99/00673, 1999.
29. Rosenbach-Belkin V, Chen L, Fiedor L, Tregub I, Paviotsky F, Brumfeld V, Salomon Y, Scherz A. Serine conjugates of chlorophyll and bacteriochlorophyll: photocytotoxicity in vitro and tissue distribution in mice bearing melanoma tumors. Photochem Photobiol 1996;64:174-81.
30. Rosenbah-Belkin V, Chen L, Fiedor L, Tregub I, Pavlotsky F, Brumfeld V, Salomon Y, A.Scherz. Chlorophyll and bacteriochlorophyll derivatives as photodynamic agents. In: Moser J, ed. Photodynamic tumor therapy: 2nd and 3rd generation photosensitizers. London: Harwood Academic Publishers, 1998. 117-26.
31. Zilberstein J, Schreiber S, Bloemers MC, Bendel P, Neeman M, Schechtman E, Kohen F, Scherz A, Salomon Y. Antivascular treatment of solid melanoma tumors with bacteriochlorophyll-serine-based photodynamic therapy. Photochem Photobiol 2001;73:257-66.
32. Kelleher DK, Thews O, Rzeznik J, Scherz A, Salomon Y, Vaupel P. Water-filtered infrared-A radiation: a novel technique for localized hyperthermia in combination with bacteriochlorophyll-based photodynamic therapy. Int J Hyperthermia 1999;15:467-74.
33. Schreiber S, Gross S, Brandis A, Harmelin A, Rosenbach-Belkin V, Scherz A, Salomon Y. Local photodynamic therapy (PDT) of rat C6 glioma xenografts with Pd-Bacteriopheophorbide leads to decreased metastases and increased animal cure compared to surgery. Int J Cancer 2001;99:279-85.
34. Mazor O, Brandis A, Gross S, Hami R, Vakrat Y, Koudinova N, Gladysh E, Kostenitz G, Orenstien A, Salomon Y, Scherz A. Pd-Bacteriopheophorbide (TOOKAD), a novel anti-vascular agent for photodynamic therapy of tumors: in vitro and in vivo studies. FISEB Eilat, Israel, 2002. Abstract book:231.
35. Schreiber S, Gross S, Harmelin A, Brandis A, Salomon Y, Sherz A. Photodynamic therapy (PDT) of rat C6 glioma xenografts with Pd-Pheophorbide (TOOKAD) leads to decreased metastases and increased animal cure compared to surgery. IPA 8th International Congress of Photodynamic Medicine. Vancouver, Canada, 2001.
36. Lee LK, Whitehurst C, Pantelides ML, Moore JV. An interstitial light assembly for photodynamic therapy in prostatic carcinoma. BJU Int 1999;84:821-6.
37. Pinthus JH, Waks T, Schindler DG, Harmelin A, Said JW, Belldegrun A, Ramon J, Eshhar Z. WISH-PC2: a unique xenograft model of human prostatic small cell carcinoma. Cancer Res 2000;60:6563-7.
38. Rembrink K, Romijn JC, van der Kwast TH, Rubben H, Schroder FH. Orthotopic implantation of human prostate cancer cell lines: a clinically relevant animal model for metastatic prostate cancer. Prostate 1997;31:168-74.
39. Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC, Chung LW. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res 1992;52:1598-605.
40. Uchida K, Itakura K, Kawakishi S, Hiai H, Toyokuni S, Stadtman ER. Characterization of epitopes recognized by 4-hydroxy-2-nonenal specific antibodies. Arch Biochem Biophys 1995;324:241-8.
41. Wan S, Parrish JA, Anderson RR, Madden M. Transmittance of non-ionising radiation in human tissue. Photochem Photobiol 1981;34:679-81.
42. Bonnett R. Photodynamic therapy in historical perspective. In: Johnson S, Johnson FN, eds. Reviews in contemporary pharmacotherapy. London: Marius Press, 1999. 1-14.
43. Fingar VH, Wieman TJ, Wiehle SA, Cerrito PB. The role of microvascular damage in photodynamic therapy: the effect of treatment on vessel constriction, permeability, and leukocyte adhesion. Cancer Res 1992;52:4914-21.
44. Fingar VH. Vascular effects of photodynamic therapy. J Clin Laser Med Surg 1996;14:323-8.
45. Fingar VH, Wieman TJ, Haydon PS. The effects of thrombocytopenia on vessel stasis and macromolecular leakage after photodynamic therapy using photofrin. Photochem Photobiol 1997;66:513-7.
46. Chatterjee SR, Srivastava TS, Kamat JP, Devasagayam TP. Lipid peroxidation induced by a novel porphyrin plus light in isolated mitochondria: possible implications in photodynamic therapy. Mol Cell Biochem 1997;166:25-33.
47. Hadjur C, Richard MJ, Parat MO, Jardon P, Favier A. Photodynamic effects of hypercin on lipid peroxidation and antioxidant status in melanoma. Photochem Photobiol 1996;64:375-81.
48. Pradhan D, Weiser M, Lumley-Sapanski K, Frazier D, Kemper S, Williamson P, Schlegel RA. Peroxidation-induced perturbations of erythrocyte lipid organization. Biochim Biophys Acta 1990;1023:398-404.
49. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hydroxynoneal, malonaldehyde and related aldehydes. Free Radic Biol Med 1991;11:81-128.
50. Halliwell B, Gutteridge JM, Free radicals in biology and medicine. Oxford: Oxford University Press, 1999.
51. Uchida K, Shiraishi M, Naito Y, Torii Y, Nakamura Y, Osawa T. Activation of stress signaling pathways by the end product of lipid peroxidation: 4-hydroxy-2-nonenal is a potential inducer of intracellular peroxide production. J Biol Chem 1999;274:2234-42.
52. Gross S, Gilead A, Scherz A, Neeman M, Salomon Y. Photodynamic therapy (PDT) of solid tumors with Pd-Bacteriopheophorbide (WST09): functional imaging by blood oxygen level-dependent (BOLD) MRI. 10th International Society for Magnetic Resonance in Medicine. Honolulu, Hawaii, 2002. Abstract 2154.
53. Grant WE, Speight PM, Hopper C, Bown SG. Photodynamic therapy: an effective, but non-selective treatment for superficial cancers of the oral cavity. Int J Cancer 1997;71:937-42.
54. Abbas F, Civantos F, Benedetto P, Soloway MS. Small cell carcinoma of the bladder and prostate. Urology 1995;46:617-30.
55. Amato RJ, Logothetis CJ, Hallinan R, Ro JY, Sella A, Dexeus FH. Chemotherapy for small cell carcinoma of prostatic origin. J Urol 1992;147:935-7.